Focus Africa 2: Pharma Business Expansion in Africa: Lessons from China’s Belt and Road Initiative
The Belt and Road Initiative (BRI), a cornerstone of China’s global development strategy, was a key focus at the Beijing Forum, emphasizing its role in transforming Africa’s infrastructure. For pharmaceutical companies from China, Europe, and the U.S., this presents a mutually beneficial opportunity.
The BRI’s expansion across Africa is laying the groundwork for efficient transport networks that can support the growth of the pharma industry, ensuring medicines reach all corners of the continent.
Africa’s pharmaceutical market is expected to reach $70 billion by 2030, and both Chinese and Western companies are racing to secure their place in this booming market. China’s infrastructure projects—building roads, ports, and railways—offer a reliable platform for global pharma firms to collaborate.
European and U.S. companies, known for their innovative healthcare technologies, can leverage China’s logistical developments to expand their footprint in Africa.
The BRI has been a game-changer in helping Africa overcome its infrastructural deficits, but the West's involvement remains critical. European and North American firms can integrate their supply chain solutions with China’s infrastructure projects to ensure the safe and efficient delivery of medicines.
By working together, global powers can maximize the benefits of Africa’s economic growth while contributing to the continent’s healthcare improvements. The result would be a more resilient, interconnected pharma network, benefiting all stakeholders involved.
